Daiwa Securities Group
DNA icon

Daiwa Securities Group’s Ginkgo Bioworks DNA Stock Holding History

Daiwa Securities Group’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,850
Closed -$57K – 1253
2025
Q4 		$57K Buy
6,850
+1,082
+19% +$11.7K ﹤0.01% 1104
2025
Q3 		$84K Sell
5,768
-552
-9% -$6.61K ﹤0.01% 1054
2025
Q2 		$71K Buy
+6,320
New +$49K ﹤0.01% 1020
2024
Q2 		– Sell
-1,477
Closed -$69K – 1332
2024
Q1 		$69K Sell
1,477
-97
-6% -$5.02K ﹤0.01% 1080
2023
Q4 		$106K Buy
1,574
+385
+32% +$23.6K ﹤0.01% 1006
2023
Q3 		$86K Hold
1,189
– – ﹤0.01% 1027
2023
Q2 		$88K Buy
1,189
+165
+16% +$9.77K ﹤0.01% 1026
2023
Q1 		$54K Buy
1,024
+201
+24% +$12.7K ﹤0.01% 1040
2022
Q4 		$56K Buy
823
+132
+19% +$12.1K ﹤0.01% 1025
2022
Q3 		$86K Buy
+691
New +$82.3K ﹤0.01% 1015

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Daiwa Securities Group's DNA Position: Q1 2026 in Review

Daiwa Securities Group sold out of Ginkgo Bioworks (DNA) in Q1 2026, closing a stake of 6,850 shares — an estimated $57K sold.

Daiwa Securities Group first reported a position in DNA in Q3 2022 and held it in 10 quarters. The position peaked at $106K in Q4 2023. 175 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

  • Daiwa Securities Group reported no remaining Ginkgo Bioworks position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 6,850 Ginkgo Bioworks shares in Q1 2026, an estimated $57K.
  • Daiwa Securities Group first reported a position in Ginkgo Bioworks in Q3 2022 and held it in 10 quarters.
  • Daiwa Securities Group's Ginkgo Bioworks position peaked at $106K in Q4 2023.
  • 175 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.